#United States #Cervical Cancer #Doral #Mel-Mont Medical #HPV mRNA

Mel-Mont Medical Wins at ASCCP

Mel-Mont Medical, a pioneering company in women's health diagnostics, has made headlines with its groundbreaking advancements in cervical cancer screening technology. The firm was honored with the Best Innovative Technology Award at the 2026 American Society for Colposcopy and Cervical Pathology (ASCCP) Scientific Meeting for its remarkable Proofer 7 HPV mRNA E6/E7 Biomarker Test. This accolade underscores the company's commitment to making cervical cancer screening more accessible and effective, especially for patients with positive HPV results.

The award-winning test is part of Mel-Mont’s comprehensive Mía™ Cervical Cancer Test, which emphasizes a patient-focused approach. As cervical cancer screenings increasingly transition towards patient-collected samples, the need for reliable and user-friendly testing methods has never been more critical. Mel-Mont's innovative solutions are addressing this by enabling easier sample collection while providing clinicians with specific risk assessments post-HPV detection.

Recent federal guidelines now favor patient-collected high-risk HPV testing for women aged 30 to 65, marking a significant shift in cervical cancer screening practices. This change is not only expected to enhance accessibility but also amplify demand for technologies that simplify the screening process while equipping healthcare providers with essential data for follow-ups after a positive HPV result.

Despite the increased efforts in cervical cancer awareness, many women remain either unscreened or under-screened. Traditional screening methods can often be cumbersome, uncomfortable, and not easily accessible. Mel-Mont’s Mía Comprehensive Cervical Cancer Test aims to dismantle these barriers through a streamlined process that combines HPV DNA detection with crucial mRNA data, thus paving a clearer path from screening to informed risk assessment.

Frank Melendez, CEO of Mel-Mont Medical, emphasizes the necessity for advancements in cervical cancer screening: _“The future of cervical cancer screening will require both better access and better answers. Mía is designed to make screening easier for patients, while Proofer 7 provides genotype-specific mRNA information that may help clinicians assess risk and guide follow-up decisions more effectively.”_

Proofer 7 sets itself apart as a cutting-edge laboratory-developed test (under PLA Code 0463U) that adds an essential triage layer following a high-risk HPV DNA result. By analyzing E6/E7 mRNA expression across seven prevalent high-risk HPV types, the test assists healthcare professionals in determining the necessary evaluations for patients and whether they should be monitored according to existing clinical guidelines and best practices.

With more than 127,000 cases evaluated globally, Proofer 7 has amassed compelling evidence supporting its efficacy in improving specificity while reducing unnecessary referrals for colposcopy in certain clinical scenarios. Mel-Mont Medical is actively pursuing partnerships with healthcare providers, systems, and women’s health organizations to broaden the clinical adoption of Mía.

Liliana Montes, COO of Mel-Mont Medical, highlights the company’s ethos: _“Our mission is to make cervical cancer screening more accessible, more actionable, and better aligned with how care is evolving.”_ The acclaim from ASCCP not only validates their innovative approach but also reinforces the essential nature of patient-focused diagnostics that enhance both the experience of patients and the informational needs of healthcare providers.

As healthcare continues to evolve, the integration of technology within medical practices, especially in areas such as cervical cancer screening, becomes increasingly paramount. Mel-Mont Medical’s unwavering commitment to innovation stands as a beacon for future advancements in women's health diagnostics, paving the way for improved health outcomes and a future where cervical cancer is more readily combated.

For detailed insights into the Mía Comprehensive Cervical Cancer Test and its implications for women's health, visit Mía Cancer Test.